Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
      • All Events
      • COVID-19
      • Diabetes
      • Immunology
      • Neuroscience
      • Oncology
      • Cardiovascular
      • COVID-19
      • Diabetes
      • Immunology
      • Men's Health
      • Neuroscience
      • Oncology
  • Medical Education
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Trulicity (dulaglutide) injection Right
  4. Can Trulicity® (dulaglutide) be used in patients with type 1 diabetes?
Search Trulicity (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Trulicity ® (dulaglutide) injection

0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can Trulicity® (dulaglutide) be used in patients with type 1 diabetes?

Dulaglutide is not approved for use in patients with type 1 diabetes.

US_cFAQ_GLP005_USE_TYPE_1_DIABETES
US_cFAQ_GLP005_USE_TYPE_1_DIABETES
en-US

See important safety information, including boxed warning, in the attached prescribing information.

Approved Indication

Dulaglutide is a glucagon-like peptide-1 receptor agonist indicated

  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and
  • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple CV risk factors.1

Dulaglutide and Type 1 Diabetes

Dulaglutide should not be used in patients with type 1 diabetes.1

Dulaglutide is not approved for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as the safety and efficacy of dulaglutide in these patient populations have not been studied.2

Dulaglutide is not a substitute for insulin.2

Enclosed Prescribing Information

TRULICITY® (dulaglutide) injection, for subcutaneous use, Lilly

References

1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: July 01, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.4 08/2022 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2022. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    Facebook Twitter
    visit www.phactmi.org
    Lilly